184 related articles for article (PubMed ID: 12924504)
1. Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571).
Naito K; Mori T; Miyazaki K; Tsukada Y; Ikeda Y; Okamoto S
Intern Med; 2003 Aug; 42(8):740-2. PubMed ID: 12924504
[TBL] [Abstract][Full Text] [Related]
2. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
4. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
[TBL] [Abstract][Full Text] [Related]
5. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
Xu Y; Wahner AE; Nguyen PL
Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
7. Low concentrations of STI571 in the cerebrospinal fluid: a case report.
Petzer AL; Gunsilius E; Hayes M; Stockhammer G; Duba HC; Schneller F; Grünewald K; Poewe W; Gastl G
Br J Haematol; 2002 Jun; 117(3):623-5. PubMed ID: 12028032
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Aleem A; Siddiqui N
Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
[TBL] [Abstract][Full Text] [Related]
10. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.
Gotoh A; Miyazawa K; Uchida Y; Sashida G; Kawakubo K; Kuriyama Y; Ohyashiki K
Int J Hematol; 2002 Feb; 75(2):191-4. PubMed ID: 11939268
[TBL] [Abstract][Full Text] [Related]
13. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
14. Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib.
Myojo T; Hino N
Intern Med; 2004 Feb; 43(2):126-30. PubMed ID: 15005255
[TBL] [Abstract][Full Text] [Related]
15. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
[No Abstract] [Full Text] [Related]
16. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
[No Abstract] [Full Text] [Related]
18. Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
Agis H; Mannhalter C; Sperr WR; Keil F; Kalhs P; Pirc-Danoewinata H; Krauth MT; Haas OA; Geissler K; Lechner K; Valent P
Leuk Lymphoma; 2004 Jul; 45(7):1453-8. PubMed ID: 15359647
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
20. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
